Novel agents for the treatment of adenocarcinoma of the pancreas

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1473-1485

  Mackenzie, R Pamela ^a   McCollum, A David ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Biologic agent; Chemotherapy; Pancreatic cancer; Targeted therapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; ENDOTAG 1; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LONAFARNIB; MARIMASTAT; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PACLITAXEL DERIVATIVE; PANITUMUMAB; PEMETREXED; PLACEBO; PROTEIN; TANOMASTAT; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TARGETING; FATIGUE; HUMAN; INFECTION; LEUKOPENIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; REVIEW; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 70350616252     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.109     Document Type: Review

References (115)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Burris H, Moore M, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997). •• Trial establishing gemcitabine as the standard of care in advanced pancreatic cancer. (Pubitemid 27251144)
3. Cheverton P, Friess H, Andras C et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). J. Clin. Oncol. 22(Suppl. 14), (2004) (Abstract 4005).
4. Lersch C, van Cutsem E, Amado R et al. Randomized Phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 20, (2001) (Abstract 608).
5. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19(15), 3447-3455 (2001). (Pubitemid 32730080)
6. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(17), 3296-3302 (2003). (Pubitemid 46606263)
7. Ychou M, Desseigne F, Guimbaud R et al. Randomized Phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 4516).
8. Burtness BA, Powell M, Berlin J et al. Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r): eastern cooperative oncology. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 4519).
9. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J. Clin. Oncol. 20(15), 3270-3275 (2002). (Pubitemid 34831525)
10. Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 16, 1639-1645 (2005). (Pubitemid 41510138)
11. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, Phase III trial of the Swiss Group For Clinical Cancer Research And The Central European Cooperative Oncology Group. J. Clin. Oncol. 25(16), 2212-2217 (2007). (Pubitemid 46954645)
12. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18), 3776-3783 (2004). (Pubitemid 41095218)
13. Abou-Alfa GK, Letourneau R, Harker G et al. Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 24(27), 4441-4447 (2006). (Pubitemid 46630982)
14. Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24(24), 3946-3952 (2006). (Pubitemid 46630743)
15. Colucci G, Labianca R, Di Costanzo et al. A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: the GIP-1 (Gruppo Italiano Pancreas-OIM/GISCAD/GOIRC) study. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4504).
16. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23(15), 3509-3516 (2005). • Disappointing results of a Phase III trial showing no improvement with oxaliplatin plus gemcitabine compared with single-agent gemcitabine. (Pubitemid 46243495)
17. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161-167 (2002). (Pubitemid 34886337)
18. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430-1438 (2004). (Pubitemid 41103625)
19. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract LBA4509).
20. Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 4508).
21. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer 3(Suppl. 4), (2005) (Abstract PS11).
22. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). •• Trial demonstrating modest, but statistically significant, improvement in survival with gemcitabine plus erlotinib over gemcitabine alone.
23. Ychou M, Dahan L, Mitry E et al. LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: definitive results of a randomized Phase III trial (FFCD 0301). Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 180).
24. Ghosn M, Farhat F, Kattan J, Saroufim A, Nasr F, Chahine G. Phase II study of sequential and modulated use of FOLFOX-6 followed by gemcitabine as the first-line treatment of locally advanced and/or metastatic pancreatic adenocarcinoma. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 196).
25. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27(13), 2231-2237 (2009).
26. Kullmann F, Hollerbach S, Dollinger MM et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre Phase II study. Br. J. Cancer 100(7), 1032-1036 (2009).
27. Fogelman DR, Varadhachary G, Xiong HQ et al. Final results of a bi-institution Phase II study of gemcitabine, oxaliplatin, and bevacizumab for advanced pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 182).
28. Picozzi VJ, Canlas LA, Sicuro PL, Malpass TW. A Phase II trial of gemcitabine, docetaxel, and bevacizumab (GDB) in metastatic pancreas cancer. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4606).
29. Ko AH, Dicke K, Gurtler J et al. Phase II, randomized, open-label study of cetuximab and bevacizumab alone or in combination with fixed-dose rate (FDR) gemcitabine as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (MPC). Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 183).
30. Yoshizawa J, Takizawa A, Takeuchi O et al. Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother. Pharmacol. DOI: 10.1007/s00280-009-0990-0 (2009) (Epub ahead of print).
31. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin. Investig. Drugs 18(3), 335-348 (2009).
32. Okusaka T, Funakoshi A, Furuse J et al. A late Phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 61(4), 615-621 (2008).
33. Strumberg D, Bergmann L, Graeven U et al. Results of a Phase II trial of S-1 for first-line treatment of patients with metastatic pancreatic cancer (CESAR-Study group). Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 195).
34. Abbruzzese JL, Lenz H, Hanna W et al. Open-label Phase II study of S-1 as second-line therapy for patients with metastatic pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 243).
35. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br. J. Cancer 94(11), 1575-1579 (2006). • Promising Phase II trial in an Asian population evaluating the combination of S-1 and gemcitabine. (Pubitemid 43924916)
36. Oh D, Choi I, Yoon S et al. A multicenter Phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium Orlando, FL, USA 25-27 January 2008 (Abstract 212).
37. Zang D, Kim J, Hwang S et al. Phase II trial of gemcitabine and S-1 combination for patients with advanced pancreas and biliary tract cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 213).
38. Nakamori S, Eguchi H, Endo W et al. Multicenter Phase II study of the combination of S-1 administration prior to gemcitabine for unresectable/ recurrent pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 251).
39. Shitara K, Komatsu Y, Yuki S et al. Pilot study of combination chemotherapy with S-1 and irinotecan (IRIS) for advanced pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium Orlando, FL, USA 25-27 January 2008 (Abstract 155).
40. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 7(8), 1041-1053 (2006).
41. Von Hoff DD, Ramanathan R, Borad M et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a Phase I/II study. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4525).
42. Saif MW, Rubin MS, Figueroa JA, Kerr RO. Multicenter Phase II trial of Genexol-PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (APC): final results. Program and Abstracts of the Gastrointestinal Cancers Symposium Orlando, FL, USA 25-27 January 2008 (Abstract 269).
43. Lohr M, Haas S, Bechstein W et al. A Phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patients with unresectable pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract LBA120). • Promising Phase II trial evaluating a novel paclitaxel formulation plus gemcitabine.
44. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13(3), 289-298 (2008).
45. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 27(3), 495-522 (2008).
46. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br. Med. Bull. 87, 97-130 (2008).
47. Ignatiadis M, Polyzos A, Stathopoulos GP et al. A multicenter Phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 71(3-4), 159-163 (2006).
48. Blaszkowsky LS, Ryan DP, Earle C et al. A Phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 15080).
49. Czito BG, Willett CG, Bendell JC et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J. Clin. Oncol. 24(4), 656-662 (2006).
50. Olsen CC, Schefter TE, Chen H et al. Results of a Phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating k-ras as a potential biomarker of response to therapy. Am. J. Clin. Oncol. 32(2), 115-121 (2009).
51. Graeven U, Kremer B, Sudhoff T et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94(9), 1293-1299 (2006).
52. Strumberg D, Scheulen ME, Hilger RA et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). J. Clin. Oncol. 24(Suppl. 18), 2006 (Abstract 12504).
53. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther. 9(2), 263-271 (2009).
54. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res. 10(10), 3327-3332 (2004). (Pubitemid 38685437)
55. Patnaik A, Pipas M, Rosen LS et al. A Phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results. J. Clin. Oncol. 26(Suppl. 15), (2008) (Abstract 3558).
56. O'Reilly EM, Niedzwiecki D, Hollis DR et al. A Phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J. Clin. Oncol. 26(Suppl. 15), (2008) (Abstract 4515).
57. Morabito A, Piccirillo MC, Falasconi F et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinses: current status and future directions. Oncologist 14(4), 378-390 (2009).
58. Spano JP, Moore M, Kim S et al. A Phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. J. Clin. Oncol. 24(Suppl. 18), (2006) (Abstract 13092).
59. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet 371(9630), 2101-2108 (2008)
60. Iqbal S, Lenz HJ, Yang D et al. A randomized Phase II study of BAY 43-9006 in combination with gemcitabine in metastatic pancreatic carcinoma: a California Cancer Consortium study (CCC-P). J. Clin. Oncol. 26(Suppl. 15), (2008) (Abstract 11082).
61. Trevino JG, Summy JM, Lesslie DP et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168(3), 962-972 (2006).
62. Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br. J. Cancer 99(7), 1074-1082 (2008).
63. Uronis HE, Bullock K, Blobe G et al. A Phase I study of gemcitabine + dasatinib (GD) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 276).
64. Hammel P, Mornex F, Deplanque G et al. Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: a multicenter Phase II study. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4617).
65. Longo R, Cacciamani F, Naso G, Gasparini G. Pancreatic cancer: from molecular signature to target therapy. Crit. Rev. Oncol. Hematol. 68(3), 197-211 (2008).
66. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59(17), 4356-4362 (1999). (Pubitemid 29418754)
67. Okami J, Yamamoto H, Fujiwara Y et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res. 5(8), 2018-2024 (1999).
68. El-Rayes BR, Zalupski MM, Shields AF et al. A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs 23(6), 583-590 (2005).
69. Kerr S, Campbell C, Legore K, Witters L, Harvey H, Lipton A. Phase II trial of gemcitabine and irinotecan in advanced adenocarcinoma of the pancreas. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 4155).
70. Ferrari V, Valcamonico F, Amoroso V et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a Phase II trial. Cancer Chemother. Pharmacol. 57, 185-190 (2006). (Pubitemid 41779837)
71. Dragovich T, Burris H 3rd, Loehrer P et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a Phase II trial. Am. J. Clin. Oncol. 31(2), 157-162 (2008).
72. Rebollo A, Martinez-A C. Ras proteins: recent advances and new functions. Blood 94(9), 2971-2980 (1999). (Pubitemid 29512700)
73. Sirivatanauksorn V, Sirivatanauksorn Y, Lemoine NR. Molecular pattern of ductal pancreatic cancer. Langenbecks Arch. Surg. 383, 105-115 (1998). (Pubitemid 28442523)
74. Adjei AA, Dy GK, Erlichman C et al. A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. 9(1), 115-123 (2003). (Pubitemid 36109723)
75. Alberts SR, Schroeder M, Erlichman C et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II trial. J. Clin. Oncol. 22(24), 4944-4950 (2004). (Pubitemid 46638619)
76. Evans JD, Cornford PA, Dodson A, Neoptolemos JP, Foster CS. Expression patterns of protein kinase C isoenzymes are characteristically modulated in chronic pancreatitis and pancreatic cancer. Am. J. Clin. Pathol. 119(3), 392-402 (2003). (Pubitemid 37047863)
77. Yoshiji H, Kuriyama S, Ways DK et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59(17), 4413-4418 (1999) (Pubitemid 29418762)
78. Partovian C, Simons M. Regulation of protein kinase B/Akt activity and Ser 473 phosphorylation by protein kinase Cα in endothelial cells. Cell. Signal. 16(8), 951-957 (2004) (Pubitemid 38638784)
79. Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E. Inhibition of protein kinase Cβ by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin. Cancer Res. 13(22), 6827-6833 (2007). (Pubitemid 350206821)
80. Carducci MA, Musib L, Kies MS et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24(25), 4092-4099 (2006). (Pubitemid 46622284)
81. Richards DA, Kuefler PR, Becerra C et al. Phase II randomized study of gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer. Program and Abstracts of the Gastrointestinal Cancers Symposium San Francisco, CA, USA 15-17 January 2009 (Abstract 189).
82. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20(10), 1218-1249 (2006). (Pubitemid 43727584)
83. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated owing to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 23(53), 8571-8580 (2004). (Pubitemid 39576463)
84. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol. Cancer 7, 64 (2008).
85. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated Akt in pancreas cancer. Br. J. Cancer 89(11), 2110-2115 (2003). (Pubitemid 38030911)
86. Yamamoto S, Tomita Y, Hoshida Y et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10(8), 2846-2850 (2004). (Pubitemid 38509164)
87. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 1(12), 989-997 (2002).
88. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60(19), 5451-5455 (2000). (Pubitemid 30761257)
89. Fujiwara M, Izuishi K, Sano T et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J. Exp. Clin. Cancer Res. 27, 76 (2008).
90. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348 (2004).
91. Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1α/VEGF signaling. IUBMB Life 59(11), 717-721 (2007). (Pubitemid 350035585)
92. Wolpin BM, Hezel AF, Abrams T et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 27(2), 193-198 (2009).
93. Buck E, Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5(11), 2676-2684 (2006). (Pubitemid 44848994)
94. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors on pancreatic cancer cells. Biochem. Pharmacol. 75(5), 1035-1044 (2008).
95. Javle MM, Xiong H, Reddy S et al. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: the results of two prospective Phase II studies. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4621).
96. Moser C, Schachtschneider P, Lang SA et al. Inhibition of insulin-like growth factor-1 receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur. J. Cancer 44(11), 1577-1586 (2008).
97. Beltran PJ, Mitchell P, Moody G et al. AMG-479, a fully human anti IGF-1 receptor antibody, inhibits PI3K/Akt signaling and exerts potent antitumor effects in combination with EGF-R inhibitors in pancreatic xenograft models. Program and Abstracts of the Gastrointestinal Cancers Symposium Orlando, FL, USA 19-21 January 2007 (Abstract 208).
98. Beltran PJ, Mitchell P, Moody G et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. J. Clin. Oncol. 26(Suppl. 15), (2008) (Abstract 4617).
99. Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch. Pathol. Lab. Med. 133(3), 413-422 (2009).
100. Feldmann G, Dhara S, Fendrich V et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67(5), 2187-2196 (2007). (Pubitemid 46424238)
101. Schlingensiepen K, Bischof A, Egger T et al. Targeted down regulation of TGF-β2 in pancreatic carcinoma: a Phase I/II dose escalation study to evaluate the safety and tolerability of the antisense oligonucleotide AP 12009. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 4253).
102. Oettle H, Hilbig A, Seufferlein T et al. Interim results of the Phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4619).
103. LoRusso P, Hong D, Heath E et al. First-in-human study of AMG 655, pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 3534).
104. Kindler HL, Garbo L, Stephenson J et al. A Phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 4501). • Early results of the combination of gemcitabine with an agonist of the TRAIL receptor 2 in advanced pancreatic cancer.
105. McConkey DJ, Zhu K. Mechanisms of proteosome inhibitor action and resistance in cancer. Drug Resist. Updat. 11(4-5), 164-179 (2008).
106. Wang H, Song X, Logsdon C et al. Proteosome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res. 69(3), 1063-1070 (2009).
107. Alberts SR, Foster NR, Morton RF et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized Phase II study. Ann. Oncol. 16(10), 1654-1661 (2005).
108. Seeliger H, Camaj P, Ischenko I et al. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol. Cancer Res. 7(2), 189-198 (2009).
109. Bennewith KL, Huang X, Ham CM et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69(3), 775-784 (2009).
110. Riley CJ, Engelhardt KP, Saldanha JW et al. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 69(5), 1933-1940 (2009).
111. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 174(3), 854-868 (2009).
112. National Cancer Institute. Surveillance Epidemiology and End Results http://seer.cancer.gov/statfacts/html/pancreas.html
113. National Library of Medicine, National Institutes of Health. Bethesda, MD, USA www.clinicaltrials.gov/ct2/results?term=pancreatic+cancer
114. Pfizer discontinues global Phase III trial of axitinib for futility in advanced pancreatic cancer www.medicalnewstoday.com/articles/137485.php
115. Trial to determine the maximum tolerated dose of Genexol-PM plus gemcitabine and evaluate efficacy and safety of Genexol-PM Regimens in Subjects with advanced pancreatic cancer http://clinicaltrials.gov/ct2/show/NCT00882973